Campbell & Co Investment Adviser’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,318	Closed	-$236K	–	1172
2023 Q1	$236K	Sell	8,318 -14,229	-63%	-$422K	0.04%	686
2022 Q4	$659K	Sell	22,547 -25,180	-53%	-$801K	0.16%	209
2022 Q3	$1.26M	Buy	47,727 +42,840	+877%	+$1.57M	0.29%	77
2022 Q2	$217K	Sell	4,887 -2,913	-37%	-$134K	0.06%	582
2022 Q1	$386K	Buy	+7,800	New	+$374K	0.1%	374
2019 Q1	–	Sell	-7,488	Closed	-$334K	–	635
2018 Q4	$334K	Buy	7,488 +2,488	+50%	+$128K	0.33%	124
2018 Q3	$347K	Buy	+5,000	New	+$379K	0.24%	164
2018 Q1	–	Sell	-4,218	Closed	-$225K	–	554
2017 Q4	$225K	Buy	+4,218	New	+$235K	0.17%	285

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Campbell & Co Investment Adviser's EGRX Position: Q2 2023 in Review

Campbell & Co Investment Adviser sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 8,318 shares — an estimated $236K sold.

Campbell & Co Investment Adviser first reported a position in EGRX in Q4 2017 and held it in 8 quarters. The position peaked at $1.26M in Q3 2022. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

Campbell & Co Investment Adviser reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Campbell & Co Investment Adviser sold 8,318 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $236K.
Campbell & Co Investment Adviser first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 8 quarters.
Campbell & Co Investment Adviser's Eagle Pharmaceuticals, Inc. position peaked at $1.26M in Q3 2022.
126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2023, filed 11 Aug 2023.